ERX-315 SUBMITTED FOR HREC APPROVAL

Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This submission marks a significant milestone for EtiraRx and approval by HREC will enable the start of phase 1 clinical trials to evaluate the safety and efficacy of ERX-315.      

ERX-315 is designed to target specific pathways that are critical for cancer cell survival and proliferation. This targeted approach helps to spare healthy cells, potentially reducing side effects commonly associated with cancer therapies.

“The submission of ERX-315 to the HREC is a pivotal step forward in bringing this groundbreaking treatment to patients who need it most,” said Russell Hayward, CEO of Etira. “This submission to the HREC is built on a significant amount of preclinical work, with state-of-the art formulation approaches and thoughtful clinical trial design and we are grateful tothe entire team for their focus, dedication and perseverance.”

Etira will provide updates on the continued progress of ERX-315 as it moves through the regulatory procedures and starts clinical trials. This trial will involve multiple research centers across Australia and will enroll participants with metastatic breast, liver, endometrial, pancreatic and ovarian cancers.